Block Copolymer Systems and Their Use in Medical Devices
The present disclosure relates to block copolymers, methods for their production, and the use of these copolymers in medical devices. In embodiments, the block copolymers may be used in tissue reinforcement including, for example, in hernia repair. The copolymers possess at least one block that is hydrophilic and fast degrading, and at least one other block that is hydrophobic and slower to degrade.
1 . A block copolymer comprising:
at least one hydrophilic block comprising a polyether; and
at least one hydrophobic block comprising a random copolymer of an unsubstituted lactone in combination with a substituted lactone.
2 . The block copolymer of claim 1 , wherein the unsubstituted lactone and the substituted lactone of the hydrophobic block are joined by hydrogen bonding.
3 . The block copolymer of claim 1 , wherein the hydrophilic block is selected from the group consisting of polyethylene oxide, polypropylene oxide, polyethylene oxide-co-polypropylene oxide, alkyl substituted ethylene oxides, polyethylene glycol, polytetramethylene ether glycol, and combinations thereof
4 . The block copolymer of claim 1 , wherein the hydrophilic block comprises a polyethylene glycol having a weight average molecular weight of from about 200 to about 10,000 Daltons.
5 . The block copolymer of claim 1 , wherein the unsubstituted lactone is selected from the group consisting of caprolactones, valerolactones, dioxanones, dioxepanones, trimethylene carbonate, propiolactones, butyrolactone, and combinations thereof
6 . The block copolymer of claim 1 , wherein the substituted lactone is selected from the group consisting of oxepan-2-ones, 7-alkyl-oxepan-2-ones, 1,3-dioxepan-2-ones, 1,5-dioxepan-2-ones, 1,4-dioxepan-2-ones, 1,3-dioxepan-4-ones, trimethylene carbonates, valerolactones, and combinations thereof.
7 . The block copolymer of claim 6 , wherein the substituted lactone is substituted with a group selected from the group consisting of C1-C10 alkyl groups, aryl groups, substituted alkyl groups, and substituted aryl groups.
8 . The block copolymer of claim 1 , wherein the substituted lactone is substituted with a group selected from the group consisting of hydroxyphenol, aminophenol, thiophenol, benzamide, and combinations thereof.
9 . The block copolymer of claim 1 , wherein the substituted lactone is substituted with a group selected from the group consisting of pyridine, pyrimidine, pyrazine, and combinations thereof
10 . The block copolymer of claim 1 , wherein ratio of the unsubstituted lactone to the substituted lactone is from about 20/80 to about 80/20.
11 . The block copolymer of claim 1 , wherein the hydrophilic block has a weight average molecular weight of from about 200 to about 10,000 Daltons, and the hydrophobic block has a weight average molecular weight of from about 1,000 to about 150,000 Daltons.
12 . The block copolymer of claim 1 , wherein the hydrophilic block degrades in vivo over a time of from about 1 day to about 30 days after implantation, and the hydrophobic block degrades in vivo over a time of from about 1 month to about 24 months after implantation.
13 . A medical device comprising the copolymer of claim 1 .
14 . The medical device of claim 13 , wherein the medical device is selected from the group consisting of hernia patches, tissue scaffolds, burn dressings, sponges, augmentation devices, breast prostheses, orthopedic devices, pins, plates, clamps, screws, vascular implants, arterial grafts, clips, staples, tacks, sutures, nerve channels, and combinations thereof.
15 . The medical device of claim 13 , wherein the medical device further comprises at least one bioactive agent.
16 . A hernia patch comprising a block copolymer comprising at least one hydrophilic block comprising an ether; and at least one hydrophobic block comprising a random copolymer of an unsubstituted lactone in combination with a substituted lactone.
17 . The hernia patch of claim 16 , wherein the unsubstituted lactone and the substituted lactone of the hydrophobic block are joined by hydrogen bonding.
18 . The hernia patch of claim 16 , wherein the hydrophilic block is selected from the group consisting of polyethylene oxide, polypropylene oxide, polyethylene oxide-co-polypropylene oxide, alkyl substituted ethylene oxides, polyethylene glycol, and combinations thereof.
19 . The hernia patch of claim 16 , wherein the hydrophilic block comprises a polyethylene glycol having a weight average molecular weight of from about 200 to about 10,000 Daltons.
20 . The hernia patch of claim 16 , wherein the unsubstituted lactone is selected from the group consisting of caprolactones, valerolactones, dioxanones, dioxepanones, trimethylene carbonate, propiolactones, butyrolactone, and combinations thereof
21 . The hernia patch of claim 16 , wherein the substituted lactone is selected from the group consisting of oxepan-2-ones, 7-alkyl-oxepan-2-ones, 1,3-dioxepan-2-ones, 1,5-dioxepan-2-ones, 1,4-dioxepan-2-ones, 1,3-dioxepan-4-ones, and combinations thereof.
22 . The hernia patch of claim 21 , wherein the substituted lactone is substituted with a group selected from the group consisting of C1-C10 alkyl groups, aryl groups, substituted alkyl groups, and substituted aryl groups.
23 . The hernia patch of claim 16 , wherein the substituted lactone is selected from the group consisting of 3-(4-hydroxybenzyl)oxepan-2-one, 3-(4-aminobenzyl)oxepan-2-one, 3-(pyridine-4-ylmethyl)oxepan-2-one, and combinations thereof.
24 . The hernia patch of claim 16 , wherein ratio of the unsubstituted lactone to the substituted lactone is from about 20/80 to about 80/20.
25 . The hernia patch of claim 16 , wherein the first block has a weight average molecular weight of from about 200 to about 10,000 Daltons, and the second block has a weight average molecular weight of from about 1,000 to about 150,000 Daltons.
26 . The hernia patch of claim 16 , wherein the hydrophilic block degrades in vivo over a time of from about 1 day to about 30 days after implantation, and the hydrophobic block degrades in vivo over a time of from about 1 month to about 24 months after implantation.
27 . The hernia patch of claim 16 , wherein the patch further comprises at least one bioactive agent.
28 . The hernia patch of claim 16 , wherein the patch comprises a film having a thickness of from about 0.1 mm to about 2 mm.